

# FILE

**Application  
for  
United States Letters Patent**

**To all whom it may concern:**

*Be it known that we,*

*Henry A. Lester, Nathan Dascal, Nancy F. Lim, Wolfgang Schreibmayer, Norman Davids  
have invented certain new and useful improvements in*

**DNA ENCODING INWARD RECTIFIER, G-PROTEIN ACTIVATED, MAMMALIAN, POTASSIUM KGA CHANNEL  
AND USES THEREOF**

*of which the following is a full, clear and exact description.*

DNA ENCODING INWARD RECTIFIER, G-PROTEIN ACTIVATED,  
MAMMALIAN, POTASSIUM KGA CHANNEL AND USES THEREOF

The invention disclosed herein was made with U.S. Government support under USPHS grants GM29836 and MH49176. Accordingly, the the U.S. government has certain rights in this invention.

Background of the invention

Throughout this application various publications are referenced by their reference number within parentheses. Full citations for these publications may be found at the end of the specification immediately preceding the sequence listing. The disclosures of these publications in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art to which this invention pertains.

Parasympathetic regulation of the rate of heart contraction is exerted through the release of acetylcholine (ACh), which opens a  $K^+$  channel in the atrium and thus slows the rate of depolarization that leads to initiation of the action potential (1,2). The coupling between binding of ACh to a muscarinic receptor and opening of the  $K^+$  channel occurs via a pertussis toxin (PTX)-sensitive heterotrimeric G-protein,  $G_k(3-5)$ , probably belonging to the  $G_i$  family (6,7). Activation of this G-protein-activated  $K^+$  channel by  $G_k$  does not require cytoplasmic intermediates (reviewed in refs. 8,9). However, a long-standing controversy exists as to which G-protein subunit couples to the KG channel. Purified  $\beta\gamma$  subunit complex (10,11) and  $\alpha$  subunits of  $G_i$  family (6,7,12) activate the KG channel in cell free, inside-out patches of atrial myocytes. Activation by the  $\alpha$  subunits

occurs at lower concentrations than that by  $\beta\gamma$ , but seems to be less efficient (13); the relative physiological importance of each pathway, as well as of possible involvement of the arachidonic acid pathway (14), is unclear.

A channel similar or identical to the ACh-operated KG can be activated in the atrium by adenosine (15), ATP (16), and epinephrine (17), probably also via a G-protein pathway. Furthermore, in nerve cells various 7-helix receptors such as serotonin 5HT<sub>1A</sub>,  $\delta$ -opioid, GABA<sub>B</sub>, somatostatin, etc., couple to similar K<sup>+</sup> channels, probably through direct activation by G-proteins (18-22). The similarity of the channels and of the signaling pathways in atrium and some nerve cell preparations was strengthened by the demonstration of the coupling of a neuronal 5HT<sub>1A</sub> receptor (5HT<sub>1A</sub>-R), transiently expressed in atrial myocytes, to the atrial KG (23).

By electrophysiological and pharmacological criteria, the atrial KGA channel belongs to a family of inward rectifiers that conduct K<sup>+</sup> much better in the inward than the outward direction, are blocked by extracellular Na<sup>+</sup>, Cs<sup>+</sup> and Ba<sup>2+</sup>, and are believed to possess a single-file pore with several permeant and blocking ion binding sites (24). Many inward rectifiers are not activated by transmitters or voltage but seem to be constitutively active. Inward rectification of the atrial KGA channel is due to block of K<sup>+</sup> efflux by intracellular Mg<sup>2+</sup> (25), but for some channels of this family inward rectification may not depend on Mg<sup>2+</sup> block (26,27). The molecular structures of atrial and neuronal KGs are unknown. Inwardly rectifying K<sup>+</sup> channels structurally similar to voltage-activated K<sup>+</sup> channels have been cloned from plant cells (28,29). Recently, the primary structures of two mammalian inward rectifier channels have been

elucidated by molecular cloning of their cDNAs via expression in *Xenopus* oocytes: an ATP-regulated K<sup>+</sup> channel from kidney, ROMK1 (30), and an inward rectifier from a macrophage cell line, IRKI (31). Both appear to belong to a new superfamily of K<sup>+</sup> channels, with only two transmembrane domains per subunit and a pore region homologous to that of K<sup>+</sup>, Ca<sup>2+</sup> and Na<sup>+</sup> voltage-dependent channels (see ref. 32). It has been hypothesized that the structure of G-protein activated inward rectifying K<sup>+</sup> channels should be similar to that of ROMK1 and IRK1 (31). Cloning of the atrial KGA channel and its expression in a heterologous system would be of importance not only for testing this hypothesis, but also because it will allow an as yet unexplored molecular approach to investigation of the mechanisms of direct G-protein-ion channel coupling. As a first step to cloning of the atrial KGA channel we have expressed it in *Xenopus* oocyte injected with atrial RNA and characterized the macroscopic current properties, including a preliminary characterization of G-protein coupling. We cloned the atrial KGA from a cDNA library derived from mRNA extracted from the heart of a 19 day old rat.

Summary of the Invention

This invention provides isolated nucleic acid molecules which encode inward rectifier, G-protein activated, mammalian, potassium KGA channel.

This invention also provides a nucleic acid molecule of at least 15 nucleotides capable of specifically hybridizing with the above nucleic acid molecule.

This invention further provides a vector comprising the isolated nucleic acid molecules encoding an inward rectifier, G-protein activated, mammalian, potassium KGA channel.

This invention provides a host vector system for the production of a polypeptide having the biological activity of KGA channel which comprises the above vector in a suitable host.

This invention also provides a method for isolating from a sample a nucleic acid molecule encoding an inward rectifier, G-protein activated, potassium channel in a sample which comprises: (a) isolating the nucleic acids from the sample; (b) contacting the isolated nucleic acids with the molecule of at least 15 nucleotides capable of specifically hybridizing with the above nucleic acid molecule which encode inward rectifier, G-protein activated, mammalian, potassium KGA channel under the conditions permitting complex formation between the nucleic acid molecule encoding an inward rectifier, G-protein activated, potassium channel and the nucleic acid molecule of at least 15 nucleotides capable of specifically hybridizing with the above nucleic acid molecule which encode inward rectifier, G-protein activated, mammalian, potassium KGA channel; (c) isolating the complex formed; and (d) separating the nucleic acid

molecule encoding an inward rectifier, G-protein activated, potassium channel from the complex, thereby isolating the nucleic acid molecule encoding an inward rectifier, G-protein activated, potassium channel.

Year	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034	2035	2036	2037	2038	2039	2040	2041	2042	2043	2044	2045	2046	2047	2048	2049	2050	2051	2052	2053	2054	2055	2056	2057	2058	2059	2060	2061	2062	2063	2064	2065	2066	2067	2068	2069	2070	2071	2072	2073	2074	2075	2076	2077	2078	2079	2080	2081	2082	2083	2084	2085	2086	2087	2088	2089	2090	2091	2092	2093	2094	2095	2096	2097	2098	2099	2100
1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034	2035	2036	2037	2038	2039	2040	2041	2042	2043	2044	2045	2046	2047	2048	2049	2050	2051	2052	2053	2054	2055	2056	2057	2058	2059	2060	2061	2062	2063	2064	2065	2066	2067	2068	2069	2070	2071	2072	2073	2074	2075	2076	2077	2078	2079	2080	2081	2082	2083	2084	2085	2086	2087	2088	2089	2090	2091	2092	2093	2094	2095	2096	2097	2098	2099	2100	

Brief Description of Figures

Figure 1.

Inward currents evoked by high  $K^+$ , 5HT and ACh in RNA-injected oocytes. (A)  $I_{hk}$  and  $I_{5HT}$  in an oocyte injected with atrial RNA + 5HT1A-R RNA. Holding potential in this and all following Figures was -80mV. (B) Inward currents evoked by ACh (AcCho) and 5HT in a single oocyte in hK solution. (C) The dependence of  $I_{5HT}$  amplitude on 5HT concentration in oocytes of one frog. In each oocyte, the response to one 5HT concentration was tested. Data represent mean  $\pm$  SEM in 4-6 cells at each concentration.

Figure 2.

$I_{hk}$  and  $I_{5HT}$  are inwardly rectifying  $K^+$  currents. (A) Currents evoked by voltage steps from the holding potential of -80 mV to voltages between -140 and 40 mV in 20 mV steps in ND96(a), hK (b), hK in the presence of 5HT (c). Net  $I_{5HT}$  (d) was obtained by digital subtraction of (b) from (c). (B) Current-voltage relations of the total membrane current in a representative oocyte in NG 96 (2 mM  $[K_{out}]$ ;  $\square$ ), in 25 mM  $[K^+_{out}]$  ( $\blacklozenge$ ); in 75 mM  $[K_{out}]$  ( $\circ$ ), and in hK (96 mM  $[K_{out}]$ ;  $\blacktriangle$ ). (C) Current-voltage relation of the net  $I_{5HT}$  in the same oocyte as in (B) in 25 mM  $[K_{out}]$  ( $\blacklozenge$ ), 75 mM  $[K_{out}]$

(○), and 96 mM [Kout] (▲). (D) The dependence of the reversal potentials of total membrane current (▲) and of  $I_{5HT}$  (●) on [Kout]. The straight lines represent least square fits to data (mean±SEM, n=3 for each point).

Figure 3.

$Ba^{2+}$  block of  $I_{hk}$  and  $I_{5HT}$ . (A-C), records taken from the same oocyte at 10 min intervals. Between the records, the cell was bathed in ND96. 5HT concentration was 4 nM. Note that in (B) 300  $\mu$ M  $Ba^{2+}$  reduces  $I_{hk}$  and almost completely blocks  $I_{5HT}$ .  $Ba^{2+}$  and 5HT were washed out simultaneously, and this resulted in an inward current "tail". (D) dose dependence of  $Ba^{2+}$  inhibition of  $I_{hk}$  in native oocytes (○),  $I_{hk}$  in RNA-injected oocytes (●),  $I_{5HT}$  in RNA-injected oocytes (▽). Data are mean±SEM, n=3 to 7 for each point.

Figure 4.

$I_{5HT}$  is mediated by activation of a G-protein. (A) The effect of PTX treatment (500 ng/ml, 20-26 h) on  $I_{hk}$  and  $I_{5HT}$ . The cells were injected with 120 ng/oocyte total atrial RNA, 11 ng/oocyte 5HT1A-R RNA, and, where indicated, with 11 ng/oocyte  $G_{i2\alpha}$  RNA: (B) GDP- $\beta$ -S injection inhibits  $I_{5HT}$  but not  $I_{hk}$  in an oocyte injected with atrial + 5HT1A-R RNAs. 5HT concentration was 0.4  $\mu$ M. A small



outward current deflection (denoted by  $\downarrow$ ) upon washout of 5HT was caused by an inadvertent perfusion of ND96 for a few seconds.

Figure 5.

Nucleotide and deduced amino acid sequence encoding the inward rectifier, G-protein associated, mammalian, potassium KGA channel. Numbers in the right hand margin correlate to nucleotide position and numbers below the amino acid sequence correlate with amino acid position.

**Detailed Description of the Invention**

5 This invention provides isolated nucleic acid molecules which encode inward rectifier, G-protein activated, mammalian, potassium KGA channel. As used herein, the term inward rectifier, G-protein activated, mammalian, potassium KGA channel encompasses any amino acid sequence, polypeptide or protein having biological activities provided by the inward rectifier, G-protein activated, mammalian, potassium KGA channel. Furthermore the G-protein activation can be  
10 either directly or indirectly, and involve one or more G-proteins.

15 In one embodiment of this invention, the isolated nucleic acid molecules described hereinabove are DNA. In other embodiments of this invention, the isolated nucleic acid molecules described hereinabove are cDNA, genomic DNA or RNA. In the preferred embodiment of this invention, the isolated nucleic acid molecule is a cDNA as shown in sequence ID number 43717.APP.  
20

25 This invention also encompasses DNAs and cDNAs which encode amino acid sequences which differ from those of inward rectifier, G-protein activated, mammalian, potassium KGA channel, but which should not produce functional changes in the KGA channel. This invention also encompasses nucleic acid molecules of at least 15 nucleotides capable of specifically hybridizing with the nucleic acid molecule which encode inward rectifier, G-protein activated, mammalian, potassium KGA channel. Hybridization methods are  
30 well known to those of skill in the art.

35 The DNA molecules of the subject invention also include DNA molecules coding for polypeptide analog, fragments or derivatives of substantially similar polypeptides which

5 differ for naturally-occurring forms in terms of the  
identity of location of one or more amino acid residues  
(deletion analogs containing less than all of the residues  
specified for the protein, substitution analogs wherein one  
10 or more residues are replaced by other residues and addition  
analog wherein one or more amino acid residues is added to  
a terminal or medial portion of the polypeptides) and which  
share some or all properties of naturally- occurring forms.  
These sequences include: the incorporation of codons  
15 preferred for expressions by selected non-mammalian host;  
the provision of sites for cleavage by restriction  
endonuclease enzymes; the addition of promoters operatively  
linked to enhance RNA transcription; and the provision of  
additional initial, terminal or intermediate DNA sequences  
that facilitate construction of readily expressed vectors.

20 The nucleic acid molecule described and claimed herein is  
useful for the information which it provides concerning the  
amino acid sequence of the polypeptide and as products for  
the large scale synthesis of the polypeptide by a variety of  
recombinant techniques. The nucleic acid molecule is useful  
for generating new cloning and expression vectors,  
transformed and transfected procaryotic and eucaryotic host  
cells, and new and useful methods for cultured growth of  
25 such host cells capable of expressing the inward rectifier,  
G-protein activated, mammalian, KGA potassium channel and  
related polypeptides with biological activity of the KGA  
channel. Capable hosts for such host vector systems may  
include but are not limited to a bacterial cell, an insect  
30 cell, a mammalian cell, and a Xenopus oocyte.

35 The isolated RNA molecule described and claimed herein is  
useful for the information it provides concerning the amino  
acid sequence of the polypeptide and as a product for  
synthesis of the polypeptide by injecting the RNA molecules

into *Xenopus* oocytes and culturing the oocytes under conditions that are well known to an ordinary artisan.

Moreover, the isolated nucleic acid molecules are useful for the development of probes to screen for and isolate related molecules from nucleic acid libraries other tissues, or organisms.

Inward rectifier, G-protein activated, mammalian, potassium KGA channel may be produced by a variety of vertebrate animals. In an embodiment, a rat inward rectifier, G-protein activated, mammalian, potassium KGA channel is isolated. A sequence of the DNA of rat inward rectifier, G-protein activated, mammalian, potassium KGA channel is shown in Figure 5.

The resulting plasmid, pBSIIKS(-)KGA, encoding the rat inward rectifier, G-protein activated, mammalian, potassium KGA channel was deposited on May 17, 1993 with the American Type Culture Collection (ATCC), 12301 Parklawn Drive, Rockville, Maryland 20852, U.S.A., under the provisions of the Budapest Treaty for the International Recognition of the Deposition of Microorganism for the Purposes of Patent Procedure. Plasmid, pBSIIKS(-)KGA, was accorded ATCC accession number 75469.

Throughout this application, references to specific nucleotides are to nucleotides present on the coding strand of the nucleic acid. The following standard abbreviations are used throughout the specification to indicate specific nucleotides:

C = cytosine	A = adenosine
T = thymidine	G = guanosine

For the purpose of illustration only, applicants used a cDNA plasmid library derived from 19-day-old rat atrial mRNA. The DNA was synthesized from the mRNA by reverse transcriptase using a poly(dt) primer with a XhoI overhang and was methylated. Adapters with EcoRI sites were ligated to both ends and the cDNA was digested with XhoI. It was ligated into XhoI-EcoRI-digested pBluescriptII KS(-). The library was linearized and amplified by polymerase chain reaction of the cDNA using primers that were complementary to sequences flanking the cDNA insert. cRNA was synthesized in vitro from the T7 promoter using T7 RNA polymerase. The cRNA was microinjected into *Xenopus laevis* oocytes and electrophysiological recordings under conditions described in Experimental Materials and Methods determined identification of a inward rectifier, G-protein activated, mammalian, potassium KGA channel. Fewer and fewer CDNA clones from the library were used after identification of the KGA channel until the cDNA of the inward rectifier, G-protein activated, mammalian, potassium KGA channel was isolated.

This invention provides a nucleic acid probe comprising a nucleic acid molecule of at least 15 nucleotides capable of specifically hybridizing with a sequence included within the sequence of a nucleic acid molecule encoding an inward rectifier, G-protein activated, mammalian, potassium KGA channel. As used herein, the phrase "specifically hybridizing" means the ability of a nucleic acid molecule to recognize a nucleic acid sequence complementary to its own and to form double-helical segments through hydrogen bonding between complementary base pairs. Nucleic acid probe technology is well known to those skill in the art who will readily appreciate that such probes may vary greatly in length and may be labeled with a detectable label, such as a radioisotope or fluorescent dye, to facilitate detection

of the probe. DNA probe molecules may be produced by insertion of a DNA molecule which encodes inward rectifier, G-protein activated, mammalian potassium KGA channel into suitable vectors, such as plasmids, bacteriophages, or retroviral vectors followed by transforming into suitable host cells and harvesting of the DNA probes, using methods well known in the art. Alternatively, probes may be generated chemically from DNA synthesizers.

The probes are useful for 'in situ' hybridization to locate tissues which express this gene, or for other hybridization assays for the presence of this gene or its in RNA in various biological tissues.

Vectors which comprise the isolated nucleic acid molecule described hereinabove also are provided. Suitable vectors comprise, but are not limited to, a plasmid or a virus. These vectors may be transformed into a suitable host cell to form a host cell vector system for the production of a polypeptide having the biological activity of inward rectifier, G-protein activated, mammalian potassium KGA channel.

This invention further provides an isolated DNA or cDNA molecule described hereinabove wherein the host cell is selected from the group consisting of bacterial cells such as *E. coli*), yeast cells, fungal cells, insect cells and animal cells. Suitable animal cells include, but are not limited to Cos cells, HeLa cells, L(tk-), and various primary mammalian cells.

This invention provides a method for isolating from a sample a nucleic acid molecule encoding an inward rectifier, G-protein activated, potassium channel using the probe generated from the rat inward rectifier, G-protein

activated, mammalian, potassium KGA channel gene. For the human, inward rectifier, G-protein activated, mammalian, potassium KGA channel, it is conceivable that the degree of homology between rat and human could be considerable. Homology studies of the inward rectifier, G-protein activated, mammalian, potassium KGA channel using Genetics Computer Group Sequence Analysis Software, Version 7.2, revealed 55% identity with Human clone HHCMD37 (Genbank Accession # M78731). Human heart cDNA library and human genomic library may be used for such screening. Duplicate filters of human libraries may be screened with radio labelled probe derived from the rat inward rectifier, G-protein activated, mammalian, potassium KGA channel DNA molecule. The filters containing the human libraries will be hybridized with the probe at low stringency (Sambrook, et al 1989) and positive clones identified.

This invention provides a method to identify and purify inward rectifier, G-protein activated, potassium channels. A sample of nucleic acid molecules can be screened for nucleic acid molecules capable of supporting complex formations with an inward rectifier, G-protein activated, mammalian, KGA potassium channels nucleic acid molecule of at least 15 nucleotides under conditions well known in the art that cause complex formation between nucleic acids molecules. "Sample" as used herein includes but is not limited to genomic libraries, cDNA libraries, nucleic acid molecule extracts from tissue, or nucleic acid molecule extracts from cell culture. Conditions that pertain to complex formation between nucleic acids are well understand by an ordinary skilled artisan and include but are not limited to suboptimal temperature, ionic concentration, and size of the nucleic acid molecule. After complex formation between the nucleic acid molecule encoding the inward rectifier, G-protein activated, mammalian, KGA potassium

channel and another nucleic acid, the other nucleic acid molecule can be isolated by methods known in the art.

5 This invention provides a method for isolating from a sample a nucleic acid molecule encoding an inward rectifier, G-protein activated, potassium channel in a sample which comprises: (a) isolating the nucleic acids from the sample; (b) contacting the isolated nucleic acids with the nucleic acid molecule of at least 15 nucleotides capable of specifically hybridizing with the nucleic acid molecule of an isolated nucleic acid molecule encoding an inward rectifier, G-protein activated, mammalian, potassium KGA channel under the conditions permitting complex formation between the nucleic acid molecule encoding an inward rectifier, G-protein activated, potassium channel and the nucleic acid molecule of at least 15 nucleotides capable of specifically hybridizing with the nucleic acid molecule of an isolated nucleic acid molecule encoding an inward rectifier, G-protein activated, mammalian, potassium KGA channel; (c) isolating the complex formed; and (d) separating the nucleic acid molecule encoding an inward rectifier, G-protein activated, potassium channel from the complex, thereby isolating the nucleic acid molecule encoding an inward rectifier, G-protein activated, potassium channel.

This invention further provides a method for isolating DNA encoding an inward rectifier, G-protein activated, potassium channel or a fragment thereof in a sample which comprises: (a) isolating the DNA from the sample; (b) denaturing the isolated DNA; (c) reannealing the denatured nucleic acids in the presence of two unique single stranded nucleic acid molecules of at least 15 nucleotides capable of specifically hybridizing with the nucleic acid molecule of the inward



rectifier, G-protein associated, mammalian, potassium KGA  
channel that are complementary to nucleotide sequences on  
opposite strands of an isolated DNA molecule encoding an  
inward rectifier, G-protein activated, mammalian, potassium  
KGA channel; (d) polymerizing the reannealed nucleic acids  
with DNA polymerase under conditions that allow DNA  
polymerization; (e) denaturing the polymerized DNA in (d);  
(f) repeating steps (c) through (e) for more than 10 cycles;  
and (g) isolating the polymerization product in step  
(f). The term "unique" as used herein defines a nucleic  
acid molecule that does not contain known genomic repeated  
sequences, including but not limited to Alu sequences.

This invention provides a method for isolating DNA encoding  
an inward rectifier, G-protein activated, potassium channel  
or a fragment thereof in a sample which comprises: (a)  
isolating the DNA from the sample; (b) denaturing the  
isolated DNA; (c) reannealing the denatured nucleic acids in  
the presence of a unique single stranded nucleic acid  
molecules of at least 15 nucleotides capable of specifically  
hybridizing with the nucleic acid molecule of the inward  
rectifier, G-protein associated, mammalian, potassium KGA  
channel that is complementary to nucleotide sequences of an  
isolated DNA molecule encoding an inward rectifier, G-  
protein activated, mammalian, potassium KGA channel and a  
single stranded nucleic acid molecule encoding a known  
genomic repeat sequence; (d) polymerizing the reannealed  
nucleic acids with DNA polymerase under conditions that  
allow DNA polymerization; (e) denaturing the polymerized DNA  
in (d); (f) repeating steps (c) through (e) for more than 10  
cycles; and (g) isolating the polymerization product in step  
(f).

This invention provides the above method for isolating from  
a sample a nucleic acid molecule encoding an inward

rectifier, G-protein activated, potassium channel in a sample wherein, the nucleic acid molecule of at least 15 nucleotides capable of specifically hybridizing with the nucleic acid molecule of an isolated nucleic acid molecule encoding an inward rectifier, G-protein activated, mammalian, potassium KGA channel is labelled with a detectable marker.

The invention provides the nucleic acid molecule isolated by the above method for isolating from a sample a nucleic acid molecule encoding an inward rectifier, G-protein activated, potassium channel in a sample.

This invention provides a purified inward rectifier, G-protein activated, mammalian, potassium KGA channel.

This invention also provides the above-described purified channel having substantially the same amino acid sequence as the amino acid sequence shown in Figure 5.

This invention provides a protein encoded by the above-described isolated nucleic acid molecule.

This invention provides a method for determining whether an agent activates a KGA channel which comprises: (a) contacting the host vector system of claim 10 with the agent under conditions permitting the KGA channel conductance to be affected by known ion channel agonists or intracellular second messenger agonists; and (b) detecting any change in KGA channel conductance, an increase in KGA channel conductance indicating that the agent activates the KGA channel. The term "agent" as used herein describes any molecule, protein, or pharmaceutical with the capability of directly or indirectly altering ion channel conductance by affecting second messenger systems or the ion channel

directly. Agents include but are not limited to serotonin, neurotrophin, enkephalins, dopamine, arachidonic acid, cholera toxin, and pertussis toxin. The term "activators" as used herein defines any agent which activates a G-protein associated receptor. The term "activates" as used herein is applied to both G-protein associated receptors and ion channel conductance and in terms of G-protein associated receptors defines the state of the receptor wherein it initiates release of a G-protein subunit which in turn initiates a cellular response. In terms of the ion channel conductance "activates" defines the state of the channel wherein the channel increases conductance. The term "deactivates" as used herein defines the state of the channel wherein the channel is initiated to decrease conductance or is incapable of conductance under conditions when the channel normally conducts ions across a membrane.

This invention also provides the agent identified by the above method.

This invention provide a pharmaceutical composition comprising an amount of the above agent effective to increase KGA conductance and a pharmaceutical acceptable carrier.

This invention provides a method for determining whether an agent deactivates KGA channel conductance which comprises: (a) contacting the host vector system for the production of a polypeptide having the biological activity of KGA channel which comprises the vector comprising the nucleic acid molecule encoding an inward rectifier, G-protein activated, mammalian, potassium KGA channel operatively linked to a promoter of RNA transcription in a suitable host with the agent under conditions permitting the KGA channel conductance to be affected by known ion channel antagonists

or intracellular second messenger system agonist; and  
(b) detecting any change in KGA channel conductance, a decrease in KGA channel conductance indicating that the agent deactivates the KGA channel. The term "agonist" as used herein defines an agent that initiates activation of ion channel conductance or initiates activation of a second messenger system. The term "antagonist" as used herein defines an agent initiates deactivation of ion channel conductance or initiates deactivation of a second messenger system.

This invention provides agents identified by the above method for determining whether an agent deactivates KGA channel conductance.

This invention provides a pharmaceutical composition comprising an amount of the above agent effective to decrease KGA channel conductance and a pharmaceutical acceptable carrier.

This invention provides a method for identifying in a nucleic acid sample a nucleic acid molecule encoding a G-protein associated receptor which activates the inward rectifier, G-protein activated, mammalian, KGA potassium channel which comprises: (a) introducing nucleic acid molecules of claim 1 and sample to a *Xenopus* oocyte under conditions permitting expression of both the receptor and the channel; (b) contacting the oocyte of step (a) with a panel of known G-protein associated receptor activators; and (c) detecting any change in KGA channel conductance, an increase in KGA channel conductance indicating the identification of a G-protein associated receptor which activates the KGA channel.

This invention provides a method for isolating from a cDNA

expression library a G-protein associated receptor which activates the inward rectifier, G-protein activated, mammalian potassium KGA channel which comprises:

(a) isolating cDNA from a sample containing a number of clones of the cDNA expression library; (b) linearizing cDNA sample if necessary; (c) transcribing the linearized cDNA; (d) isolating the RNA from the transcribed cDNA; (e) introducing the isolated RNA and nucleic acid molecules of claim 1 into a *Xenopus* oocyte under conditions permitting expression of the KGA channel and G-protein associated receptor; (f) contacting the oocyte of step (e) with a panel of known G-protein associated receptor activators; (g) detecting change in KGA channel conductance; and (h) repeating steps (a) through (g) when an increase in KGA channel conductance is detected in step (g) using fewer cDNA clones from the sample until isolation of a single cDNA clone encoding a G-protein associated receptor which activates the KGA channel.

The invention provides a cDNA encoding the G-protein associated receptor isolated in the above method for isolating from a cDNA expression library a G-protein associated receptor which activates the inward rectifier, G-protein activated, mammalian potassium KGA channel.

The invention provides a G-protein associated receptor isolated in the above method for isolating from a cDNA expression library a G-protein associated receptor which activates the inward rectifier, G-protein activated, mammalian potassium KGA channel.

This invention provides a method for testing whether a G-protein associated receptor activates the inward rectifier, G-protein activated, mammalian, KGA potassium channel which comprises: (a) introducing a nucleic acid molecule of claim

1 and a nucleic acid molecule encoding the G-protein associated receptor to a *Xenopus* oocyte under conditions permitting expression of both the receptor and the channel; (b) contacting the oocyte of step (a) with a known G-protein associated receptor activator; and (c) detecting any change in KGA channel conductance, an increase in KGA channel conductance indicating that the G-protein associated receptor activates the KGA channel.

This invention provides a method for identifying in a nucleic acid sample a G-protein associated receptor capable of deactivating the inward rectifier, G-protein activated, mammalian KGA potassium channel comprising: (a) introducing nucleic acid molecule of claim 1, nucleic acid molecule of a G-protein associated receptor known to activate the KGA channel, and sample of isolated nucleic acids to a *Xenopus* oocyte under conditions permitting expression of the G-protein associated receptor that activates the KGA channel, the KGA channel and a known G-protein associated receptor ; (b) contacting the oocyte of step (a) with a known G-protein associated receptor activator and a panel of known G-protein associated receptor activators; and (c) detecting any change in KGA channel conductance, a decrease in KGA channel conductance indicating the identification of an G-protein associated receptor capable of deactivating the KGA channel in the sample.

This invention provides a method for isolating from a cDNA expression library an G-protein associated receptor which deactivates the inward rectifier, G-protein activated, mammalian potassium KGA channel which comprises: (a) isolating cDNA from a sample containing a number of clones of the cDNA expression library; (b) linearizing cDNA sample if necessary; (c) transcribing the linearized cDNA; (d) isolating the RNA from the transcribed cDNA; (e)

introducing the isolated RNA, nucleic acid molecule encoding a known G-protein associated receptor which activates the KGA channel, and nucleic acid molecules of claim 1 into a Xenopus oocyte under conditions permitting expression of the KGA channel and both receptors; (f) contacting the oocyte of step (e) with a known G-protein associated receptor activator and a panel of known inhibitory G-protein associated activators; (g) detecting any change in KGA channel conductance,; and (h) repeating steps (a) through (g) when a decrease in KGA channel conductance is detected in step (g) using fewer number of cDNA clones from the sample until isolation of a single cDNA clone encoding an inhibitory G-protein associated receptor which deactivates the KGA channel.

The invention provides a cDNA encoding the G-protein associated receptor isolated by the above method for isolating from a cDNA expression library a G-protein associated receptor which deactivates the inward rectifier, G-protein activated, mammalian potassium KGA channel.

The invention provides a G-protein associated receptor capable of deactivating the inward rectifier, G-protein activated, mammalian potassium KGA channel isolated by the above method for isolating from a cDNA expression library a G-protein associated receptor which deactivates the inward rectifier, G-protein activated, mammalian potassium KGA channel.

This invention provides a method for identifying an inhibitory G-protein associated receptor which deactivates the inward rectifier, G-protein activated, mammalian KGA potassium channel comprising: (a) introducing the nucleic acid molecule encoding an inward rectifier, G-protein activated, mammalian, potassium KGA channel, a G-protein

associated receptor known to activate the KGA channel, and nucleic acid molecules encoding an inhibitory G-protein associated receptor to a *Xenopus* oocyte under conditions permitting expression of both the receptors and the channel;  
5 (b) contacting the oocyte of step (b) with a known G-protein associated receptor activator and a known inhibitory G-protein associated receptor activator; and (c) detecting any change in KGA channel conductance, a decrease in KGA channel conductance indicating that the G-protein associated  
10 receptor deactivates the KGA channel.

This invention provides an antibody directed against the purified inward rectifier, G-protein activated, mammalian, potassium KGA channel. In an embodiment, this antibody is  
15 monoclonal antibody.

This invention will be better understood from the Experimental Details which follow. However, one skilled in the art will readily appreciate that the specific methods and results discussed are merely illustrative of the  
20 invention as described more fully in the claims which follow thereafter.



## EXPERIMENTAL MATERIALS AND METHODS

**Preparation of RNA and oocytes.** Total RNA was extracted from atria and ventricles of 19-21 day old rats of both sexes using the Chomczynski-Sacchi procedure (33). Poly (A) RNA was separated on an oligo-dT cellulose column (type 3, Collaborative Biochemical Products). Ventricle poly(A) RNA was fractionated by centrifugation (18 h, 30,000 g, 4°C) on a linear 5%-25% sucrose gradient. *Xenopus laevis* oocytes were prepared as described (34) and injected with either 50-120 ng/oocyte poly(A) RNA, 120-200 ng/oocyte total RNA, or 35 ng/oocyte fractionated poly(A) RNA. In most cases, 5HT<sub>1A</sub>-R RNA (5-20 ng/oocyte) was co-injected with atrial or ventricle RNA. Final volume of the injected RNA solution was 50 nl. The oocytes were incubated for 3-7 days in the NDE solution (ND96 (see below) containing 1.8 mM CaCl<sub>2</sub> and supplemented with 2.5 mM Na-pyruvate and 50 µg/ml gentamicin). Occasionally, either 2.5-5% heat-inactivated horse serum or 0.5 mM theophylline were added to the NDE solution. Incubation of oocytes in pertussis toxin (PTX; List Biochemicals) was done in NDE solution without the addition of pyruvate, serum or theophylline. cDNAs of 5HT<sub>1A</sub> receptor (see 23) and G<sub>i2</sub>α (a gift from M. I. Simon, Caltech) in pBluescript were linearized, and RNA was synthesized *in vitro* as described (34).

**Electrophysiological recordings** were performed using the two electrode voltage clamp method with the Dagan 8500 amplifier (Dagan Instruments, Minneapolis) as described (35). The oocytes were usually kept in the ND96 solution: 96 mM NaCl/2 mM KCl/1 mM MgCl<sub>2</sub>/1 mM CaCl<sub>2</sub>/5 mM Hepes, pH=7.5. Most measurements were done in the high K<sup>+</sup> solution (hK): 96 mM KCl/2 mM NaCl/1 mM MgCl<sub>2</sub>/1 mM CaCl<sub>2</sub>/5 mM Hepes, pH=7.5. Solutions containing intermediate concentrations of K<sup>+</sup> were made by substituting K<sup>+</sup> for Na<sup>+</sup>. Solution exchange and drug

5

## EXPERIMENTAL RESULTS

To express the KG channel, the oocytes were injected with atrial total or poly(A) RNA. In order to avoid the possibility that a low level of expression of the muscarinic receptor will make undetectable even a well-expressed KG channel, atrial RNA was usually supplemented with mRNA coding for the serotonin-5HT1A receptor (5HT1A-R); oocytes injected with this RNA mixture will be termed RNA-injected oocytes throughout the paper. When expressed in atrial myocytes, the 5HT1A-R efficiently coupled to the KG channel normally existing in these cells (23), and it was expected to do so in the oocytes.

Four to 5 days after RNA injection addition of 10  $\mu$ M ACh or 1-2  $\mu$ M 5HT to the ND96 bath solution did not cause any significant change in membrane current. Therefore, the effects of ACh and 5HT were tested in a high potassium (hK) solution with 96 mM  $K^+$  and 2 mM  $Na^+$ . In this solution, the  $K^+$  equilibrium potential ( $E_K$ ) is close to 0 mV, and this enables inward  $K^+$  current flow through inwardly rectifying K channels at negative holding potentials (-80 mV was routinely used in this study).

Changing ND 96 to the hK solution was accompanied by the development of an inward current that reached a steady level within 0.5-1 min ( $I_{hk}$ ; Fig 1A).  $I_{hk}$  was also observed in native (not injected with any RNA) oocytes, or in oocytes injected with 5HT1A-R RNA alone, but it was always larger in RNA-injected oocytes ( $P < 0.001$ , two-tailed t-test; Table 1).

Table 1

Inward currents evoked by high  $K^+$  and by 5HT. The entries are inward currents in nA shown as mean $\pm$ SEM (n), measured at -80mV in the hK solution. 5HT concentration ranged in different experiments from 100 nM to 2  $\mu$ M.

Injected RNA	$I_{hk}$	$I_{5HT}$
None (native oocytes)	72 $\pm$ 6 (34)	0 (18)
5HT1A-R	54 $\pm$ 4 (11)	0 (12)
Atrial + 5HT1A-R	123 $\pm$ 8 (55)	290 $\pm$ 43 (55)

In RNA-injected oocytes, application of 5HT or ACh in hK solution induced an inward current ( $I_{5HT}$ ) that subsided upon washout of the transmitter (Fig. 1A, B). The response to ACh was usually smaller than to 5HT when measured in the oocytes of the same frog (Fig. 1B). Thus, in oocytes of one frog  $I_{5HT}$  was 1102 $\pm$ 84 nA (n=6), whereas the ACh response was 382 $\pm$ 45 nA (n=6).  $I_{5HT}$  tended to decrease on repeated applications of 5HT, and this could be overcome by increasing the intervals between applications to 10 min or more, suggesting the presence of a desensitization process.  $I_{5HT}$  and an increased (in comparison with native oocytes)  $I_{hk}$  were also observed in oocytes injected with ventricle poly (A) RNA + 5HT1A-R RNA, but the  $I_{5HT}$  was about 20 times smaller than with atrial poly(A) RNA (not shown). 5HT had no effect in oocytes injected with atrial RNA without the 5HT1A-R RNA (n=4) or with 5HT1A-R RNA alone, or in native oocytes (Table 1).

The 5HT dose-response curve showed saturation at about 100 nM and a half-maximal response at about 15 nM (Fig. 1C), which is characteristic of the 5HT1 receptor class (36). A similar current was evoked by a selective 5HT1A agonist, 8-OH DPAT (8-OH-2-(D1-n-(propylamino)-tetralin; data not

shown).

The current-voltage (I-V) characteristic of the oocyte membrane was studied by applying voltage steps from a holding potential of -80 mV. In normal ND96, in the range -140 - -20 mV, only voltage- and time-independent "leak" currents were observed (Fig. 2a), and the I-V curve was linear (Fig. 2B). Above -20 mV, a slowly developing outward current was observed (Fig. 2A, a-c); this is known to be due to opening of a  $\text{Cl}^-$  channel activated by  $\text{Ca}^{2+}$  entry through voltage-dependent  $\text{Ca}^{2+}$  channels (37). The  $\text{Ca}^{2+}$ -activated  $\text{Cl}^-$  current was also seen in the hK solution; in addition, the total membrane current evoked by steps to -120 and up to -20 mV was larger than in ND96 (Fig. 2Ab; 2B), whereas above 0 mV there was little or no change. This suggested that most or all of  $I_{\text{hk}}$  elicited at -80 mV by the exchange of ND96 to hK solution was due to a  $\text{K}^+$  current flowing through a constitutively active inward rectifier  $\text{K}^+$  channel(s). This current showed some time-dependent inactivation at -140 mV (Fig. 2Ab) and at more negative potentials (not shown); this inactivation phenomenon was not studied further. In the presence of 5HT, the membrane currents between -140 and -20 mV were further increased (Fig. 2Ac). Net 5HT-evoked currents, obtained by digital subtraction of total membrane currents in the absence of 5HT from currents in its presence (Fig. 2Ad), showed clear inward rectification; the 5HT-activated channels conducted little or no current above  $E_{\text{K}}$  at different external  $\text{K}^+$  concentrations,  $[\text{K}_{\text{out}}]$  (Fig. 2C). The extrapolated reversal potential of  $I_{\text{5HT}}$  showed an almost perfect selectivity of the 5HT-activated channel to  $\text{K}^+$ , changing by about 58 mV per 10-fold change in  $[\text{K}_{\text{out}}]$  (Fig. 2D). The reversal potential of the total membrane current in the absence of 5HT also depended on  $[\text{K}_{\text{out}}]$  (Fig. 2B) but changed only by 24 mV per tenfold change in  $[\text{K}_{\text{out}}]$  (Fig. 2D). This does not necessarily imply poor ion selectivity of the

constitutively active inward rectifier, but may reflect the relatively high contribution of  $\text{Cl}^-$  and  $\text{Na}^+$  to the resting membrane conductance (38).

5 Block by external  $\text{Ba}^{2+}$  is one of the characteristic features of inward rectifiers (24). In normal ND96 solution,  $\text{Ba}^{2+}$  (5  $\mu\text{M}$ -3 mM) did not cause any significant changes in resting current or conductance in native or RNA-injected oocytes at the holding potential of -80mV. In the hK solution,  $\text{Ba}^{2+}$   
10 inhibited both  $I_{\text{hK}}$  and  $I_{\text{5HT}}$  (Fig. 3), and this was accompanied by a decrease in membrane conductance (not shown). 300  $\mu\text{M}$ ,  $\text{Ba}^{2+}$  blocked about 20% of  $I_{\text{hK}}$  but almost completely abolished  $I_{\text{5HT}}$  (Fig. 3B). The  $\text{IC}_{50}$  (half-inhibition concentration) for  $\text{Ba}^{2+}$  block of  $I_{\text{5HT}}$  was about 15  $\mu\text{M}$ , whereas  $\text{IC}_{50}$  for  $I_{\text{hK}}$  block was above 3 mM (Fig. 3D). It is noteworthy that, although the sensitivity of  $I_{\text{hK}}$  to  $\text{Ba}^{2+}$  block was similar in native and RNA-injected oocytes, the latter did appear to have a small component of  $I_{\text{hK}}$  inhibited by low doses of  $\text{Ba}^{2+}$  (Fig. 3D). This raises the possibility that the atrial  $I_{\text{hK}}$  is more sensitive to  $\text{Ba}^{2+}$  block than the oocyte's  $I_{\text{hK}}$ , or that a fraction of the highly  $\text{Ba}^{2+}$ -sensitive channels underlying  $I_{\text{5HT}}$  could be active in the absence of agonist. Note also that there was an inward current "tail" observed when  $\text{Ba}^{2+}$  and 5HT was washed out simultaneously (Fig. 3B), presumably because the rate-limiting step in deactivation of the channel proceeds more slowly than unblock from  $\text{Ba}^{2+}$ .  
25

To estimate the size of RNA encoding the expressed inward rectifiers, ventricle poly(A) RNA (available in large amounts) was fractionated on a sucrose gradient. The size  
30 distribution of the fractions was measured by RNA gel blots probed with [ $^{32}\text{P}$ ]-labeled poly(T) (39). The RNA encoding  $I_{\text{5HT}}$  was found mainly in two size fractions covering the range between 2.5 and 5.5 kb. The peak expression of ventricle  $I_{\text{hK}}$   
35 was in lower size fractions, in the 1.5-3 kb range (data not

shown).

In atrium, the muscarinic receptor is coupled to the KG channel via a PTX-sensitive G-protein (8). Surprisingly, in RNA-injected oocytes,  $I_{5HT}$  was not affected by treatment with PTX; neither was  $I_{hk}$  (Fig. 4A). To test whether the 5HT1A receptor couples to the  $K^+$  channel via a G-protein, the oocytes were injected with 400-800 pmole/oocyte of the non-hydrolysable analog of GDP, GDP- $\beta$ -S, that is known to inhibit the activity of PTX-sensitive as well as of PTX-insensitive G-proteins (40). In 4 cells, GDP- $\beta$ -S injection had no effect on  $I_{hk}$  ( $115 \pm 8\%$  of control) but strongly inhibited  $I_{5HT}$ , to  $4 \pm 1\%$  of control (Fig. 4B). Thus, it appears that the coupling between the 5HT1A receptor and the KG channel occurs via an oocyte's endogenous PTX-insensitive G-protein.

We examined whether an overexpressed PTX-sensitive  $\alpha$  subunit of a G-protein, e.g.  $G_{i2}\alpha$ , could compete with the "native" PTX-insensitive  $\alpha$  subunit for the expressed 5HT1A receptor, thus restoring the PTX sensitivity of the KG channel activation. As shown in Fig. 4A, in oocytes injected with atrial RNA plus cRNAs encoding 5HT1A-R and  $G_{i2}\alpha$ , PTX inhibited  $I_{5HT}$  by about 50% ( $P < 0.01$ , two-tailed t-test), whereas  $I_{hk}$  was unaffected.

## EXPERIMENTAL DISCUSSION

5 The present results demonstrate for the first time that the  
atrial inward rectifier  $K^+$  (KG) channel, which in the native  
tissue is activated by ACh via a PTX-sensitive G-protein, is  
expressed in oocytes injected with atrial RNA. Current  
through the channel can be activated by acetylcholine (ACh)  
or, if RNA encoding a neuronal 5HT1A receptor is co-injected  
with atrial RNA, by serotonin (5HT). Activation of the  
10 channel probably occurs via a muscarinic ACh receptor  
synthesized following atrial RNA injection, rather than via  
the oocyte's endogenous muscarinic receptor. The latter  
couples to phospholipase C, and its activation induces very  
characteristic large transient  $Cl^-$  current responses caused  
15 by  $Ca^{2+}$  release from intracellular stores (41). Fortunately,  
the majority of oocyte batches lose this response after  
defolliculation (42), and this response was not observed in  
the present study. Because the ACh-evoked currents were  
small in most cases, we concentrated on the study of the 5HT  
20 response; the latter was undoubtedly mediated by the  
introduced 5HT1A receptor, as 5HT was ineffective in oocytes  
not injected with 5HT1A-RNA, and the response displayed the  
expected pharmacological properties.

25 The evidence presented here indicates that, in oocytes  
injected with atrial and 5HT1A-R RNAs, activation of the  
5HT1A receptor leads to opening of a  $K^+$  channel that bears  
distinctive features of an anomalous rectifier, similar to  
those of the atrial KG: i) it conducts inward but not  
30 outward  $K^+$  current; ii) it is blocked by low concentrations  
of  $Ba^{2+}$ , iii) the conductance of the channel does not depend  
solely on voltage but on  $(E-E_K)$ . The expression of this  
channel must truly be directed by atrial RNA, because: i) no  
hormone or transmitter-activated current of this kind is  
35 observed in native oocytes; ii) expression of 5HT1A receptor



alone does not cause the appearance of such a response. Based on ventricle RNA fractionation data, the RNA encoding the 5HT-activated channel is in a broad size range between 2.5 and 5.5 kb. This is similar or somewhat smaller than the reported 4-5 kb mRNA size of some constitutively active inward rectifiers expressed in *Xenopus* oocytes (43, 44), as well as of the cloned IRK1 (5.5 kb; ref. 31) and ROMK1 (4 kb; ref. 30) channels. The properties of  $I_{5HT}$  directed by ventricle and atrial RNA are very similar, and it is reasonable to assume that they are encoded by the same RNA species.

Opening of the inward rectifier by 5HT is mediated by activation of a G-protein, as expected for the KG channel, because i) 5HT<sub>1A</sub> receptor belongs to the family of 7-helix receptors all of which act via G-proteins (40); ii)  $I_{5HT}$  was inhibited by intracellular injection of GDP- $\beta$ -S. However, the G-protein participating in this pathway was PTX-insensitive, possibly an endogenous oocyte G-protein. It is not clear why in the oocyte the channel activation pathway involves a PTX-insensitive G-protein. The atrial KG channel normally couples to  $G_i$  (9), and there are at least two subspecies of  $G_i$  in the oocyte (45); also, some  $G_i$  may be expressed from atrial RNA. Also, in the hippocampus, the 5HT<sub>1A</sub> receptor opens a  $K^+$  channel by activating a PTX-sensitive G-protein (21). one possibility is that a vast excess of this undefined PTX-insensitive G-protein overrides the others in competition for coupling to the 5HT<sub>1A</sub> receptor. Whatever the reason for this unexpected coupling, our results show that the PTX sensitivity of the KG channel activation can be partially restored by overexpression of the  $\alpha$  subunit of  $G_i$ . Since the actual identify of the  $\alpha$  subunit does not seem to be important for activation of the expressed KG channel, these results imply that the  $\beta\gamma$  subunit complex doublet may be the activator of the channel

in this case (cf. 10, 11).

Atrial and ventricle RNAs also induce an enhanced activity of an additional inward rectifier, that is active in the absence of any specific stimulation (referred to as  $I_{hk}$  in this paper).  $I_{hk}$  in atrial RNA-injected oocytes is about twice as large as in native oocytes or oocytes injected with 5HT1A-R RNA alone. This current does not appear to represent the "basal" activity of the same channel activated by 5HT or ACh because it has a much lower sensitivity to  $Ba^{2+}$  block. Moreover, the fractionation data indicates that the RNA directing the expression of  $I_{hk}$  is smaller than that encoding the KG channel. However, it is not clear whether this atrial (or ventricle) RNA encodes the channel itself or a factor that enhances the expression or the activity of a native channel. Further studies, such as expression cloning, will help to identify the messages encoding the two inward rectifiers whose expression is reported here.

**References**

1. Sakmann, B., Noma, A. & Trautwein, W. (1983) Nature 303:250-253.
2. Ijima, T., Irisawa, H. & Kameyama, M. (1985) J. Physiol. (London) 359:485-501.
3. Pfaffinger, P.G., Martin, J.M., Hunter, D.D., Nathanson, N.M. & Hille, B. (1985) Nature 317:536-538.
4. Breitweiser, G.E. & Szabo, G. (1985) Nature 317:538-540.
5. Kurachi, Y., Nakajima, T. & Sugimoto, T. (1986) Am. J. Physiol. 251:H681-H684.
6. Yatani, A., Codina, J., Brown, A.M. & Birnbaumer, L. (1987) Science 235:207-211.
7. Yatani, A., Mattera, R., Codina, J., Graf, R., Okane, K., Pardell, E., Iyengar, R., Brown, A.M. & Birnbaumer, L. (1988) Nature 336:680-682.
8. Kurachi, Y., Tung, R.T., Ito, H. & Nakajima, T. (1992) Prog. Neurobiol. 39:229-246.
9. Brown, A.M. & Birnbaumer, L. (1990) A. Rev. Physiol. 52:197-213.
10. Logothetis, D.E., Kurachi, Y., Galper, J., Neer, E.J. & Clapham, D.E. (1987) Nature 325:321-326.
11. Kurachi, Y., Ito, H., Sugimoto, T., Katada, T. & Ui, M. (1989) Pflugers Arch. 413:325-327.

12. Codina, J., Yatani, A., Grenet, D., Brown, A.M. & Birnbaumer, L. (1987) *Science* 236:442-445.
- 5 13. Ito, H., Tung, T.T., Sugimoto, T., Kobayashi, I., Takahashi, K., Katada, T., Ui, M. & Kurachi, Y. (1992) *J. Gen. Physiol.* 99:961-983.
- 10 14. Kim, D., Lewis, D.L., Graziadei, L., Neer, E.J., Barsagi, D. & Clapham, D.E. (1989) *Nature* 337:557-560.
- 15 15. Kurachi, Y., Nakajima, T., & Sugimoto, T. (1986) *Pflugers Arch.* 407:264-276.
- 16 16. Friel, D.D. & Bean, B.P. (1990) *Pflugers Arch.* 415:651-657.
- 20 17. Kurachi, Y., Ito, H., Sugimoto, T., Shimizu, T., Miki, I. & Ui, M. (1989) *Pflugers Arch.* 414:102-104.
- 25 18. Codina, J., Grenet, D., Yatani, A., Birnbaumer, L. & Brown, A.M. (1987) *FEBS Letters*, 216:104-106.
19. North, R.A., Williams, J.T., Suprenant, A. & Christie, M.J. (1987) *Proc. Natl. Acad. Sci. USA* 84:5487-5491.
20. Andrade, R., Malenka, R.C. & Nicoll, R.A. (1986) *Science* 234:1261-1265.
- 30 21. Andrade, R. & Nicoll, R.A. (1987) *J. Physiol.* 394:99-124.
- 35 22. VanDongen, A.M.J., Codina, J., Olate, J., Mattera, R., Joho, R., Birnbaumer, L. & Brown, A.M. (1988) *Science* 242:1433-1437.

23. Karschin, A., Ho, B.Y., Labarca, G., Elroy-Stein, O., Moss, B., Davidson, N. & Lester, H.A. (1991) Proc. Natl. Acad. Sci. USA 88:5694-5698.
- 5 24. Hille, B. (1992) *Ionic Channels of Excitable Membranes*, 2nd edition (Sinauer, Sunderland, Mass).
25. Horie, M. & Irisawa, H. (1987) Am. J. Physiol. 253:H210-H214.
- 10 26. Ciani, S., Krasne, S., Myazaki, S. & Hagiwara, S. (1978) J. Membr. Biol. 44:103-134.
27. Silver, M.R. & DeCoursey, T.E. (1990) J. Gen. Physiol. 96:109-133.
- 15 28. Sentenac H., Bonneaud N., Minet M., Lacroute F., Salmon J.-M., Gaymard F. & Grignon C. (1992) Science 256:663-665.
- 20 29. Anderson J.A., Huprikar S.S., Kochian L.V., Lucas W.J. & Gaber R.F. (1992) Proc. Natl. Acad. Sci. USA 89:3736-3740.
- 25 30. Ho, K., Nichols, C.G., Lederer, W.J., Lytton, J., Vassilev, P.M., Kanazirska, M.V. & Hebert, S.C. (1993) Nature 362:31-38.
- 30 31. Kubo, Y., Baldwin, T.J., Jan, Y.N. & Jan, L.Y. (1993) Nature 362:127-132.
32. Aldrich, R. (1993) Nature 362:107-108.
- 35 33. Chomczynski, P. & Sacchi, N. (1987) Anal. Biochem. 162:156-159.

34. Dascal, N. & Lotan, I. (1992) in *Methods in Molecular Biology*, v. 13: *Protocols in Molecular Neurobiology*, eds. Longstaff, A & Revest, P. (Humana Press, Totowa, NJ).
35. Dascal, N., Ifune, C., Hopkins, R., Snutch, T.P., Lubbert, H., Davidson, N., Simon, M., & Lester, H.A. (1986) *Mol. Brain Res.* 1:201-209.
36. Hoyer, D. & Schoeffer, P. (1991) *J. Recept. Res.* 11:197-214.
37. Barish, M.E. (1983) *J. Physiol. (London)* 342:309-325.
38. Dascal, N., Landau, E.M. & Lass, Y. (1984) *J. Physiol. (London)* 352:551-574.
39. Lubbert, H., Snutch, T.P., Dascal, N., Lester, H.A. & Davidson, N. (1987) *J. Neurosci.* 7:1159-1165.
40. Gilman, A.G. (1987) *A. Rev. Biochem.* 56:615-649.
41. Dascal, N. (1987) *CRC Crit. Rev. Biochem.* 22:317-387.
42. Miledi, R. & Woodward, R.M. (1989) *J. Physiol.* 416:601-621.
43. Lewis, D.L., Ikeda, S.R., Aryee, D. & Joho, R.H. (1991) *FEBS Lett.* 290:17-21.
44. Perier, F., Coulter, K.L., Radeke, C.M. & Vanderberg, C.A. (1992) *J. Neurochem.* 59:1971-1974.
45. Olate, J., Martinez, S., Purcell, P., Jorguera, H., Codina, J., Birnbaumer, L. & Allende, J.E. (1990) *FEBS*

Lett. 268:27-31.